JP2017505121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505121A5 JP2017505121A5 JP2016545932A JP2016545932A JP2017505121A5 JP 2017505121 A5 JP2017505121 A5 JP 2017505121A5 JP 2016545932 A JP2016545932 A JP 2016545932A JP 2016545932 A JP2016545932 A JP 2016545932A JP 2017505121 A5 JP2017505121 A5 JP 2017505121A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- sequence shown
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000006052 T cell proliferation Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000002825 functional assay Methods 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 102000051957 human ERBB2 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400009 | 2014-01-09 | ||
| DKPA201400009 | 2014-01-09 | ||
| PCT/EP2014/050340 WO2014108483A1 (en) | 2013-01-10 | 2014-01-09 | Inert format |
| EPPCT/EP2014/050340 | 2014-01-09 | ||
| PCT/EP2014/064326 WO2015001085A1 (en) | 2013-07-05 | 2014-07-04 | Humanized or chimeric cd3 antibodies |
| EPPCT/EP2014/064326 | 2014-07-04 | ||
| PCT/EP2015/050276 WO2015104346A1 (en) | 2014-01-09 | 2015-01-08 | Humanized or chimeric cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205910A Division JP7208129B2 (ja) | 2014-01-09 | 2019-11-14 | ヒト化またはキメラｃｄ３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505121A JP2017505121A (ja) | 2017-02-16 |
| JP2017505121A5 true JP2017505121A5 (enExample) | 2018-02-15 |
| JP6619342B2 JP6619342B2 (ja) | 2019-12-11 |
Family
ID=52143134
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522644A Active JP6546162B2 (ja) | 2013-07-05 | 2014-07-04 | ヒト化またはキメラｃｄ３抗体 |
| JP2016545932A Active JP6619342B2 (ja) | 2014-01-09 | 2015-01-08 | ヒト化またはキメラｃｄ３抗体 |
| JP2019114397A Active JP7104000B2 (ja) | 2013-07-05 | 2019-06-20 | ヒト化またはキメラｃｄ３抗体 |
| JP2019205910A Active JP7208129B2 (ja) | 2014-01-09 | 2019-11-14 | ヒト化またはキメラｃｄ３抗体 |
| JP2022042394A Active JP7389833B2 (ja) | 2014-01-09 | 2022-03-17 | ヒト化またはキメラｃｄ３抗体 |
| JP2022109476A Active JP7757247B2 (ja) | 2013-07-05 | 2022-07-07 | ヒト化またはキメラｃｄ３抗体 |
| JP2023196008A Pending JP2024026114A (ja) | 2014-01-09 | 2023-11-17 | ヒト化またはキメラｃｄ３抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522644A Active JP6546162B2 (ja) | 2013-07-05 | 2014-07-04 | ヒト化またはキメラｃｄ３抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019114397A Active JP7104000B2 (ja) | 2013-07-05 | 2019-06-20 | ヒト化またはキメラｃｄ３抗体 |
| JP2019205910A Active JP7208129B2 (ja) | 2014-01-09 | 2019-11-14 | ヒト化またはキメラｃｄ３抗体 |
| JP2022042394A Active JP7389833B2 (ja) | 2014-01-09 | 2022-03-17 | ヒト化またはキメラｃｄ３抗体 |
| JP2022109476A Active JP7757247B2 (ja) | 2013-07-05 | 2022-07-07 | ヒト化またはキメラｃｄ３抗体 |
| JP2023196008A Pending JP2024026114A (ja) | 2014-01-09 | 2023-11-17 | ヒト化またはキメラｃｄ３抗体 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US10465006B2 (enExample) |
| EP (4) | EP3016681B1 (enExample) |
| JP (7) | JP6546162B2 (enExample) |
| KR (4) | KR102531517B1 (enExample) |
| CN (5) | CN105722529B (enExample) |
| AU (4) | AU2014286116A1 (enExample) |
| BR (1) | BR122023002590B1 (enExample) |
| CA (1) | CA2915575A1 (enExample) |
| CY (1) | CY1122840T1 (enExample) |
| DK (2) | DK3016681T5 (enExample) |
| EA (1) | EA201690167A1 (enExample) |
| ES (2) | ES2776706T3 (enExample) |
| FI (2) | FI4249515T3 (enExample) |
| HK (1) | HK1231369A1 (enExample) |
| HR (2) | HRP20200382T1 (enExample) |
| HU (2) | HUE048722T2 (enExample) |
| IL (4) | IL311371B2 (enExample) |
| LT (2) | LT3016681T (enExample) |
| ME (1) | ME03675B (enExample) |
| MX (2) | MX373245B (enExample) |
| NZ (1) | NZ715896A (enExample) |
| PL (1) | PL3016681T3 (enExample) |
| PT (2) | PT3016681T (enExample) |
| RS (2) | RS60131B1 (enExample) |
| SG (2) | SG11201510739TA (enExample) |
| SI (2) | SI3016681T1 (enExample) |
| SM (2) | SMT202000287T1 (enExample) |
| UA (1) | UA119646C2 (enExample) |
| WO (2) | WO2015001085A1 (enExample) |
| ZA (1) | ZA201800385B (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX380176B (es) * | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| SI3221359T1 (sl) | 2014-11-17 | 2020-08-31 | Regeneron Pharmaceuticals, Inc. | Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20 |
| CN107074955B (zh) | 2014-11-20 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子 |
| RS60615B1 (sr) | 2014-11-20 | 2020-08-31 | Hoffmann La Roche | Zajednički laki lanci i postupci upotrebe |
| CN114478792A (zh) | 2015-01-08 | 2022-05-13 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| IL256562B2 (en) * | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION |
| CN105296421B (zh) * | 2015-11-24 | 2019-01-29 | 高岱清 | 一种双特异性抗体活化的t细胞及制备方法与应用 |
| IL257696B2 (en) | 2015-12-09 | 2024-11-01 | Hoffmann La Roche | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| BR112018016281A2 (pt) * | 2016-03-22 | 2019-01-02 | F. Hoffmann-La Roche Ag | molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo |
| FI3433280T3 (fi) * | 2016-03-22 | 2023-06-06 | Hoffmann La Roche | Proteaasin aktivoimia t-solubispesifisiä molekyylejä |
| AU2018276419A1 (en) | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| UA128304C2 (uk) * | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CN116836285A (zh) * | 2017-03-09 | 2023-10-03 | 健玛保 | 针对pd-l1的抗体 |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| CN110913895B (zh) * | 2017-05-08 | 2024-04-02 | 阿迪马布有限责任公司 | 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法 |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| US20190100587A1 (en) * | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| CN107860925B (zh) * | 2017-11-03 | 2019-07-12 | 合肥瀚科迈博生物技术有限公司 | 用于检测血清中HuA21抗体的ELISA检测试剂盒 |
| CN109971725B (zh) * | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | 抗体修饰的嵌合抗原受体修饰t细胞及其用途 |
| AU2019222666B2 (en) * | 2018-02-15 | 2025-12-04 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
| EP3765493A2 (en) * | 2018-03-12 | 2021-01-20 | Genmab A/S | Antibodies |
| JP7377590B2 (ja) * | 2018-03-14 | 2023-11-10 | ノビミューン エスアー | 抗ｃｄ３イプシロン抗体およびそれを使用する方法 |
| DK3797121T3 (da) * | 2018-05-23 | 2024-07-08 | Pfizer | Antistoffer, der er specifikke for CD3, og anvendelser deraf |
| RS66901B1 (sr) * | 2018-05-24 | 2025-07-31 | Janssen Biotech Inc | Anti-cd3 antitela i njihova upotreba |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| WO2020076970A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| TW202506736A (zh) | 2018-10-11 | 2025-02-16 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| JP7621948B2 (ja) * | 2018-12-04 | 2025-01-27 | ノバルティス アーゲー | Ｃｄ３に対する結合分子及びその使用 |
| BR112021023048A2 (pt) | 2019-05-21 | 2022-04-19 | Novartis Ag | Moléculas de ligação a cd19 e usos das mesmas |
| WO2021048423A1 (en) | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| IL293994A (en) | 2019-12-23 | 2022-08-01 | Denali Therapeutics Inc | Progranulin variants, compositions comprising same and uses thereof |
| US20230057263A1 (en) * | 2020-01-06 | 2023-02-23 | Cytomx Therapeutics, Inc. | Single-and multi-chain polypeptides that bind specifically to cd3 epsilon |
| CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
| US20230075244A1 (en) * | 2020-02-20 | 2023-03-09 | The Feinstein Institutes For Medical Research | Agonist antibodies against endoglin and uses thereof |
| AU2021236906A1 (en) | 2020-03-18 | 2022-08-18 | Genmab A/S | Antibodies binding to B7H4 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| US20230227570A1 (en) | 2020-05-08 | 2023-07-20 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| KR20230017841A (ko) | 2020-05-27 | 2023-02-06 | 얀센 바이오테크 인코포레이티드 | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 |
| CA3187085A1 (en) | 2020-08-25 | 2022-03-03 | Manuel Baca | Multi-specific antigen binding molecules targeting hiv and methods of use |
| EP4208200A2 (en) | 2020-09-02 | 2023-07-12 | Genmab A/S | Antibody therapy |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| JP2023541860A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| BR112023004319A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma difuso de grandes células b |
| CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| BR112023004296A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma de célula b grande difusa em um indivíduo humano |
| CN116438198A (zh) | 2020-10-02 | 2023-07-14 | 健玛保 | 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体 |
| KR102671734B1 (ko) * | 2021-04-13 | 2024-06-04 | 건국대학교 글로컬산학협력단 | 개과 동물의 CD3ε 특이적 항체 또는 그의 항원 결합 단편 |
| TW202244059A (zh) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥 |
| MX2023012408A (es) | 2021-04-30 | 2023-10-31 | Hoffmann La Roche | Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b. |
| JP2024519212A (ja) | 2021-05-07 | 2024-05-09 | ジェンマブ エー／エス | Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物 |
| CN115558023A (zh) * | 2021-07-02 | 2023-01-03 | 安源医药科技（上海）有限公司 | 抗cd3抗体及其用途 |
| JP7503215B2 (ja) | 2021-10-08 | 2024-06-19 | ジェンマブ エー／エス | Ｃｄ３０及びｃｄ３に結合する抗体 |
| US20230303693A1 (en) | 2022-01-28 | 2023-09-28 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| KR20240135663A (ko) | 2022-01-28 | 2024-09-11 | 젠맵 에이/에스 | 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 |
| KR20240164782A (ko) | 2022-03-23 | 2024-11-20 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체와 화학요법의 병용 치료 |
| KR20250004776A (ko) | 2022-04-13 | 2025-01-08 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법 |
| WO2023198839A2 (en) | 2022-04-13 | 2023-10-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| AU2023266445A1 (en) * | 2022-05-09 | 2024-11-28 | Hangzhou Viromab Biotech Co., Ltd. | Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| EP4612179A1 (en) | 2022-11-02 | 2025-09-10 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating richter's syndrome |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
| WO2024213754A1 (en) | 2023-04-13 | 2024-10-17 | Genmab A/S | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 |
| WO2025057225A1 (en) * | 2023-09-14 | 2025-03-20 | Invitrogen Bioservices India Private Limited | Engineered antibodies and uses thereof |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061994A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025116732A1 (en) * | 2023-12-01 | 2025-06-05 | Rijksuniversiteit Groningen | Methods and kits for detecting proliferating cells |
| WO2025199352A2 (en) | 2024-03-20 | 2025-09-25 | Juno Therapeutics, Inc. | Antibodies specific for solute carrier family 34 member 2 (slc34a2) |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| WO2004035607A2 (en) * | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| CN101115771B (zh) * | 2005-02-03 | 2013-06-05 | 安迪拓普有限公司 | 人类抗体和蛋白质 |
| CN101155832B (zh) | 2005-02-08 | 2013-02-06 | 一般财团法人化学及血清疗法研究所 | 抗体的改良方法 |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| TWI323734B (en) | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ES2856451T3 (es) * | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| AU2008234019B2 (en) * | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| MX2009013816A (es) | 2007-06-21 | 2010-02-24 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos. |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| DE102008039957A1 (de) | 2008-08-27 | 2010-03-04 | Continental Automotive Gmbh | Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| FR2935974B1 (fr) | 2008-09-15 | 2010-10-08 | Centre Nat Rech Scient | Derives de metalloporphyrines, nanoparticules les comprenant |
| AU2009299794B2 (en) * | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| JP2012505654A (ja) * | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| CN102369021B (zh) | 2008-12-19 | 2016-09-07 | 宏观基因有限公司 | 共价双抗体及其用途 |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US8786135B2 (en) | 2010-03-25 | 2014-07-22 | Mitsubishi Electric Research Laboratories, Inc. | Wireless energy transfer with anisotropic metamaterials |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CA3051311A1 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 |
| JP5934203B2 (ja) * | 2010-07-14 | 2016-06-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌモノクローナル抗体およびこの使用 |
| TW201208703A (en) * | 2010-08-17 | 2012-03-01 | Roche Glycart Ag | Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody |
| RU2013110876A (ru) | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | Активируемые биспецифические антитела |
| CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| LT2647707T (lt) * | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| BR112013021473A2 (pt) | 2011-02-23 | 2020-08-04 | F. Hoffmann-La Roche Ag | anticorpos contra il33r humano e seus usos |
| JP2014514314A (ja) * | 2011-04-20 | 2014-06-19 | ゲンマブ エー／エス | Ｈｅｒ２およびｃｄ３に対する二重特異性抗体 |
| ME03440B (me) | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| UA115439C2 (uk) * | 2012-01-27 | 2017-11-10 | Протена Біосаєнсиз Лімітед | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| MX2016000272A (es) * | 2013-07-12 | 2016-08-03 | Zymeworks Inc | Construcciones de unión a los antígenos cd19 y cd3 biespecificos. |
| KR102357961B1 (ko) * | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| CN114478792A (zh) * | 2015-01-08 | 2022-05-13 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| IL256562B2 (en) | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| CH713600A2 (de) | 2017-03-21 | 2018-09-28 | Digi Sens Ag | Vorrichtung und Verfahren zum Messen einer Last. |
| EP3668898B1 (en) * | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| CN116406293A (zh) * | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| BR112023004296A2 (pt) * | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma de célula b grande difusa em um indivíduo humano |
| CA3190349A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| JP2023541860A (ja) * | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
-
2014
- 2014-07-04 ME MEP-2020-54A patent/ME03675B/me unknown
- 2014-07-04 EP EP14737200.7A patent/EP3016681B1/en active Active
- 2014-07-04 LT LTEP14737200.7T patent/LT3016681T/lt unknown
- 2014-07-04 SG SG11201510739TA patent/SG11201510739TA/en unknown
- 2014-07-04 ES ES14737200T patent/ES2776706T3/es active Active
- 2014-07-04 KR KR1020227004568A patent/KR102531517B1/ko active Active
- 2014-07-04 JP JP2016522644A patent/JP6546162B2/ja active Active
- 2014-07-04 KR KR1020237015498A patent/KR102813816B1/ko active Active
- 2014-07-04 RS RS20200307A patent/RS60131B1/sr unknown
- 2014-07-04 CN CN201480048350.3A patent/CN105722529B/zh active Active
- 2014-07-04 NZ NZ715896A patent/NZ715896A/en unknown
- 2014-07-04 CA CA2915575A patent/CA2915575A1/en active Pending
- 2014-07-04 PT PT147372007T patent/PT3016681T/pt unknown
- 2014-07-04 CN CN202110540502.3A patent/CN113248615B/zh active Active
- 2014-07-04 AU AU2014286116A patent/AU2014286116A1/en not_active Abandoned
- 2014-07-04 WO PCT/EP2014/064326 patent/WO2015001085A1/en not_active Ceased
- 2014-07-04 KR KR1020257017076A patent/KR20250078622A/ko active Pending
- 2014-07-04 KR KR1020167002903A patent/KR102363220B1/ko active Active
- 2014-07-04 SG SG10201800982QA patent/SG10201800982QA/en unknown
- 2014-07-04 PL PL14737200T patent/PL3016681T3/pl unknown
- 2014-07-04 MX MX2015017487A patent/MX373245B/es active IP Right Grant
- 2014-07-04 DK DK14737200.7T patent/DK3016681T5/da active
- 2014-07-04 EA EA201690167A patent/EA201690167A1/ru unknown
- 2014-07-04 IL IL311371A patent/IL311371B2/en unknown
- 2014-07-04 SM SM20200287T patent/SMT202000287T1/it unknown
- 2014-07-04 HR HRP20200382TT patent/HRP20200382T1/hr unknown
- 2014-07-04 IL IL290613A patent/IL290613B2/en unknown
- 2014-07-04 EP EP19217231.0A patent/EP3693385A1/en active Pending
- 2014-07-04 UA UAA201600940A patent/UA119646C2/uk unknown
- 2014-07-04 US US14/902,757 patent/US10465006B2/en active Active
- 2014-07-04 SI SI201431520T patent/SI3016681T1/sl unknown
- 2014-07-04 HU HUE14737200A patent/HUE048722T2/hu unknown
- 2014-07-04 BR BR122023002590-3A patent/BR122023002590B1/pt active IP Right Grant
-
2015
- 2015-01-08 ES ES23174159T patent/ES3038421T3/es active Active
- 2015-01-08 JP JP2016545932A patent/JP6619342B2/ja active Active
- 2015-01-08 CN CN202510481586.6A patent/CN120365424A/zh active Pending
- 2015-01-08 CN CN201580013100.0A patent/CN106255507B/zh active Active
- 2015-01-08 EP EP15700081.1A patent/EP3091998B1/en active Active
- 2015-01-08 PT PT231741596T patent/PT4249515T/pt unknown
- 2015-01-08 HR HRP20251127TT patent/HRP20251127T1/hr unknown
- 2015-01-08 WO PCT/EP2015/050276 patent/WO2015104346A1/en not_active Ceased
- 2015-01-08 HU HUE23174159A patent/HUE072527T2/hu unknown
- 2015-01-08 SM SM20250322T patent/SMT202500322T1/it unknown
- 2015-01-08 FI FIEP23174159.6T patent/FI4249515T3/fi active
- 2015-01-08 CN CN202410218077.XA patent/CN118063621A/zh active Pending
- 2015-01-08 EP EP23174159.6A patent/EP4249515B1/en active Active
- 2015-01-08 DK DK23174159.6T patent/DK4249515T3/da active
- 2015-01-08 SI SI201532077T patent/SI4249515T1/sl unknown
- 2015-01-08 LT LTEP23174159.6T patent/LT4249515T/lt unknown
- 2015-01-08 HK HK17104925.3A patent/HK1231369A1/zh unknown
- 2015-01-08 RS RS20250910A patent/RS67220B1/sr unknown
- 2015-01-08 US US15/110,414 patent/US10407501B2/en active Active
- 2015-12-15 IL IL243127A patent/IL243127B/en active IP Right Grant
- 2015-12-16 MX MX2020004503A patent/MX2020004503A/es unknown
-
2018
- 2018-01-19 ZA ZA2018/00385A patent/ZA201800385B/en unknown
-
2019
- 2019-06-20 JP JP2019114397A patent/JP7104000B2/ja active Active
- 2019-08-19 US US16/544,376 patent/US11613575B2/en active Active
- 2019-09-25 US US16/582,428 patent/US20200123255A1/en active Pending
- 2019-11-14 JP JP2019205910A patent/JP7208129B2/ja active Active
-
2020
- 2020-03-16 CY CY20201100224T patent/CY1122840T1/el unknown
- 2020-04-28 AU AU2020202792A patent/AU2020202792B9/en active Active
- 2020-08-05 IL IL276530A patent/IL276530B/en unknown
-
2022
- 2022-03-17 JP JP2022042394A patent/JP7389833B2/ja active Active
- 2022-06-03 AU AU2022203851A patent/AU2022203851B2/en active Active
- 2022-07-07 JP JP2022109476A patent/JP7757247B2/ja active Active
-
2023
- 2023-02-14 US US18/109,708 patent/US20230374131A1/en active Pending
- 2023-11-17 JP JP2023196008A patent/JP2024026114A/ja active Pending
-
2025
- 2025-10-24 AU AU2025256200A patent/AU2025256200A1/en active Pending
- 2025-12-09 FI FIC20250036C patent/FIC20250036I1/fi unknown